Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta.
<h4>Background</h4>A relatively large proportion of relapsing-remitting multiple sclerosis (RRMS) patients do not respond to interferon-beta (IFNb) treatment. In previous studies with peripheral blood mononuclear cells (PBMC), we identified a subgroup of IFNb non-responders that was char...
Guardado en:
Autores principales: | Marta F Bustamante, Ramil N Nurtdinov, Jordi Río, Xavier Montalban, Manuel Comabella |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2e4f0faa57a649f18031ca8a922b4fa5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
por: Lisa G M van Baarsen, et al.
Publicado: (2008) -
Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.
por: Sunny Malhotra, et al.
Publicado: (2011) -
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop F, et al.
Publicado: (2013) -
Early stage and long term treatment of multiple sclerosis with interferon-&beta;
por: Angela Applebee, et al.
Publicado: (2009) -
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Slobodan M Jankovic
Publicado: (2010)